These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 15390061

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 4. [Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
    Rouco I, Gómez JC, Lezcano E, Aniel-Quiroga MA, Velasco F, Barcena J, Pérez Bas M, Hurtado P, Cruz Lachén M, Zarranz JJ.
    Neurologia; 2006 Apr; 21(3):119-23. PubMed ID: 16575624
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 7. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
    Vaamonde J, Flores JM, Weisser R, Ibañez R, Obeso JA.
    Mov Disord; 2009 Apr 15; 24(5):762-5. PubMed ID: 19224589
    [Abstract] [Full Text] [Related]

  • 8. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A.
    Mov Disord; 1993 Apr 15; 8(2):158-64. PubMed ID: 8474482
    [Abstract] [Full Text] [Related]

  • 9. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
    Roth J, Růzicka E, Mecír P.
    Cas Lek Cesk; 1994 Nov 07; 133(21):665-7. PubMed ID: 7805088
    [Abstract] [Full Text] [Related]

  • 10. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, Di Rosa E, Martino G, Marconi R, La Spina P, Nicita-Mauro V, Di Rosa AE.
    Arch Gerontol Geriatr Suppl; 2004 Nov 07; (9):291-6. PubMed ID: 15207426
    [Abstract] [Full Text] [Related]

  • 11. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Nov 07; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M, Saéz D.
    Rev Med Chil; 1995 Mar 07; 123(3):326-9. PubMed ID: 8525172
    [Abstract] [Full Text] [Related]

  • 14. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A.
    Funct Neurol; 1992 Mar 07; 7(4):295-8. PubMed ID: 1427361
    [Abstract] [Full Text] [Related]

  • 15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov 07; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 16. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May 07; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 17. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 07; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 18. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P, Del Dotto P, Napolitano A, Pardini C, Bonuccelli U.
    Riv Neurol; 1990 Feb 07; 60(6):221-3. PubMed ID: 2100046
    [Abstract] [Full Text] [Related]

  • 19. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM, Helscher RJ, Sattler AP.
    Wien Klin Wochenschr; 1993 Feb 07; 105(16):472-5. PubMed ID: 8212705
    [Abstract] [Full Text] [Related]

  • 20. [Apomorphine in Parkinson disease].
    Gilhus NE.
    Tidsskr Nor Laegeforen; 1991 Oct 30; 111(26):3166-9. PubMed ID: 1948940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.